Open AccessNew hope for Parkinson's disease treatment: Targeting gut microbiota
Author(s) -
Fan HongXia,
Sheng Shuo,
Zhang Feng
Publication year - 2022
Publication title -
cns neuroscience and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.403
H-Index - 69
eISSN - 1755-5949
pISSN - 1755-5930
DOI - 10.1111/cns.13916
Subject(s) - gut flora , gut–brain axis , pathogenesis , parkinson's disease , disease , immune system , microbiome , enteric nervous system , immunology , medicine , biology , bioinformatics , neuroscience , pathology
There might be more than 10 million confirmed cases of Parkinson's disease (PD) worldwide by 2040. However, the pathogenesis of PD is still unclear. Host health is closely related to gut microbiota, which are affected by factors such as age, diet, and exercise. Recent studies have found that gut microbiota may play key roles in the progression of a wide range of diseases, including PD. Changes in the abundance of gut bacteria, such as Helicobacter pylori , Enterococcus faecalis , and Desulfovibrio , might be involved in PD pathogenesis or interfere with PD therapy. Gut microbiota and the distal brain achieve action on each other through a gut‐brain axis composed of the nervous system, endocrine system, and immune system. Here, this review focused on the current understanding of the connection between Parkinson's disease and gut microbiota, to provide potential therapeutic targets for PD.